The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates.


A study to evaluate the safety and immunogenicity of a yeast derived recombinant DNA hepatitis B vaccine (Engerix-B) was conducted in healthy newborn infants born to low risk European mothers negative for hepatitis B surface antigen (HBsAg). The vaccination schedule using 20 micrograms doses was administered intramuscularly at 0, 1 and 6 months. The… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.